Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemcentinib + Erlotinib in Advanced NSCLC
NCT02424617Phase 2Completed
- Sponsor
- BerGenBio ASA
- Start
- Apr 2015
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bemcentinib in non-small cell lung cancer (NSCLC), sponsored by BerGenBio ASA. Started Apr 2015; status: completed.
02
Drugs
bemcentinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02424617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02424617.